Command Palette

Search for a command to run...

IOLCP

100.59-1.32%
Market Cap
₹2,993.98 Cr
Stock P/E
28.51
ROCE
8.86%
ROE
6.13%
Book Value
₹58.65

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Public
Others

From Last Concall

POSITIVES
  • Q1 FY26 opened with solid top-line growth and margin expansion.
  • EcoVadis Silver Medal recognition signals sustainability leadership.
NEGATIVES
  • API pricing pressures and soft pricing environment in FY26.
  • Paracetamol demand remains weaker post-COVID, signaling a slower rebound.

Peers Summary

Sector Leader

IOL Chemicals And Pharmaceuticals Ltd. is currently underperforming in terms of growth and profitability metrics compared to its peers in the Pharmaceuticals & Drugs sector. However, companies like Cipla Ltd. and Dr. Reddy's Laboratories Ltd. stand out as strong performers due to their robust profitability and growth. IOL's low debt levels provide some stability, but its negative revenue growth and lower margins indicate potential challenges ahead. Investors may find better opportunities among the top performers in this sector.

Key Points
  • IOL Chemicals shows negative revenue growth (-3.8% YoY) and lower profitability metrics compared to peers.
  • Cipla Ltd. and Dr. Reddy's Laboratories are leading in profitability and growth metrics, making them attractive picks.
  • IOL's low debt-to-equity ratio (0.0203) is a positive indicator of financial stability.
Top Performers
Cipla Ltd.

Strong revenue growth (13.28% YoY) and high ROE (16.63%) with an attractive PE ratio (23.73).

Dr. Reddy's Laboratories Ltd.

High profitability with ROE of 21.76% and a low PE ratio of 15.50, making it a value pick.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.